Position in IBIO
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$4,127
-$240,124 QoQ
Shares Held
2,173
-98.3% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in IBIO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026UBS Group AG holds $8,307,109,707 across 562 Biotechnology names. IBIO ranks #492 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
22,619,472 | $626,559,372 | |
| 2 | PTGX |
Protagonist Therapeutics, Inc
|
5,177,796 | $545,739,697 | |
| 3 | ABVX |
Abivax S.A.
|
4,547,406 | $506,353,656 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
4,386,791 | $426,615,424 | |
| 5 | INSM |
INSMED Inc
|
1,737,481 | $284,112,890 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
630,618 | $281,596,158 | |
| 7 | APLS |
Apellis Pharmaceuticals, Inc.
|
6,206,681 | $249,694,775 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
299,979 | $231,775,770 |
All Filings in IBIO
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,127 | 2,173 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $244,251 | 126,556 | Shares | Defined | 2026-01-29 | |
| 2025-09-30 | $0 | 1 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $21,737 | 28,603 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $104,077 | 25,890 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $2,202 | 899 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $2 | 1 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $85,811 | 40,669 | Shares | Defined | 2024-08-14 | |
| 2024-03-31 | $7,620 | 1,877 | Shares | Defined | 2024-05-13 | |
| 2023-12-31 | $24,659 | 18,000 | Shares | Defined | 2024-02-09 | |
| No filing history on record for this holder in this stock. | ||||||